Prediction: Wall Street's Latest Stock-Split Stock -- Up 60,120% Year-to-Date -- Is Going to Implode... It's Just a Matter of Time

While AI optimism has fueled market gains, stock splits, particularly in non-tech sectors, have also contributed to market momentum; Fastenal, O'Reilly Automotive, and Interactive Brokers Group have all completed forward splits in 2025. However, Regencell Bioscience, a clinical-stage TCM company, recently underwent a 38-for-1 split despite lacking revenue and having a going concern warning, suggesting the stock is overvalued and likely to implode.

Analysis

The current equity market rally, initiated in October 2022, is significantly propelled by advancements in artificial intelligence, with PwC forecasting a $15.7 trillion boost to the global economy by 2030 from AI. Alongside AI, investor enthusiasm for stock splits in high-performing companies has also contributed to market buoyancy. Forward stock splits, which cosmetically lower a share price and increase outstanding shares without altering market capitalization or operational performance, are often perceived positively, signaling strong execution and innovation. In 2025, a notable trend has emerged with non-technology companies undertaking forward splits. Fastenal (FAST) completed a 2-for-1 split on May 21, its ninth such split, reflecting a stock value increase of over 210,000% since its 1987 IPO, driven by its strong U.S. economic ties and supply chain integration. O'Reilly Automotive (ORLY) effected a 15-for-1 split on June 9, reducing its share price from nearly $1,400 to around $90; the company benefits from an aging U.S. vehicle fleet (average age 12.8 years) and a significant share repurchase program ($25.9 billion spent since 2011, retiring over 59% of shares). Interactive Brokers Group (IBKR) executed its first-ever 4-for-1 split on June 17, supported by double-digit growth in accounts, platform equity, and trading activity, fueled by technology investments. In stark contrast, Regencell Bioscience Holdings (RGC), a clinical-stage traditional Chinese medicine firm, implemented a 38-for-1 forward split on June 13, reducing its share price from $595 to under $16. Despite a staggering year-to-date gain of 60,120% (as of June 17) and a market valuation approaching $39 billion, Regencell has generated no revenue since commencing operations in 2015, reported a $4.32 million comprehensive loss on $4.74 million in operating expenses in fiscal 2024, and employs only 12 staff, with just four in R&D. The company faces substantial risks, including no commercialized products, an inability to demonstrate successful large-scale studies or obtain regulatory approvals, and a "going concern" warning, indicating its current assets may not cover liabilities over the next year. The extreme stock appreciation is likely due to momentum trading in a previously low-float stock rather than a short squeeze, given muted overall short interest despite high borrow rates. This fundamental disconnect suggests an imminent and severe price correction for RGC.

Key Decisions for Investors

• Investors should exercise extreme caution and likely avoid Regencell Bioscience (RGC) due to its lack of revenue, significant operating losses, 'going concern' warning, and a valuation disconnect from its fundamental performance, despite its recent stock split and extreme share price appreciation.
• While stock splits, particularly forward splits, can generate positive sentiment and improve trading liquidity, investment decisions should primarily be based on a company's underlying fundamentals, operational performance, and growth prospects, as seen with Fastenal, O'Reilly Automotive, and Interactive Brokers, rather than the split event itself.
• The recent prevalence of stock splits in non-tech sectors like industrial supplies, auto parts, and financial services highlights the importance of evaluating companies on their individual merits; high-flying stocks performing splits, especially those with weak fundamentals like RGC, warrant significant skepticism and rigorous due diligence.